Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial
Purpose Chemotherapy-induced nausea and vomiting (CINV) remain significant clinical problems, especially in the delayed phase (24-120 h after chemotherapy). Amisulpride is a dopamine D2/D3-receptor...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
Supportive care in cancer
Year: 2018, Volume: 27, Issue: 7, Pages: 2699-2705 |
| ISSN: | 1433-7339 |
| DOI: | 10.1007/s00520-018-4564-8 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1007/s00520-018-4564-8 Verlag, Volltext: https://link.springer.com/article/10.1007/s00520-018-4564-8 
|
| Author Notes: | J. Herrstedt, Y. Summers, K. Jordan, J. von Pawel, A.H. Jakobsen, M. Ewertz, S. Chan, J.D. Naik, M. Karthaus, S. Dubey, R. Davis, G.M. Fox |
| Summary: | Purpose Chemotherapy-induced nausea and vomiting (CINV) remain significant clinical problems, especially in the delayed phase (24-120 h after chemotherapy). Amisulpride is a dopamine D2/D3-receptor... |
|---|---|
| Item Description: | First online: 28 November 2018 Gesehen am 22.07.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1433-7339 |
| DOI: | 10.1007/s00520-018-4564-8 |